Diorasis Therapeutics Appoints Richard A. Kresch, MD, to Board of Directors
Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Richard A. Kresch, MD, to its Board of Directors.
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Dimitri Azar, MD, MBA, AM (hon.), DHL (hon.), to its Board of Directors.
